Main menu:

April 2021


Lucentis Genentech Novartis Agreement

These structural and cross-holding links have enabled Genentech, Roche and Novartis to implement a common market strategy. The three companies have strong financial incentives to separate Avastin and Lucentis. The use of Avastin in place of Lucentis for eye injection could result in a significant loss of revenue for each of the three companies, given the different prices of the two drugs and the practice of revealing a series of syringes containing a single vial of Avastin. And the development of Avastin as an alternative to Lucentis was a “measure” to keep The price of Lucentis very high. The structural links created by the licensing agreements between them have also enabled them to be aware of the respective behaviour of their partners and, therefore, to ensure that they all follow the same line. For more information on safety, please visit Lucentis for full prescription information available here: The Authority considered that the three laboratories – Novartis, Roche and Genentech – should be examined as the “only collective entity” within the meaning of competition law, which accuses the cross-holdings and contractual ties between them, including the licensing agreements between Genentech and Novartis, on the one hand, for the marketing of Lucentis and between Gentech and Roche, on the other hand, for the marketing of Avastin. The use of Avastin in place of Lucentis would result in a considerable loss of revenue for each of the three laboratories: there is no longer any doubt in this case: Roche and Novartis have entered into an anti-competitive agreement, to artificially promote the sale of Lucentis (Novartis) in favour of Avastin (Roche), two effective drugs in the treatment of exudive maculophaty, but one (Lucentis) much more expensive than the other (Avast). “It took 10 years and 4 different levels of evaluation,” said Ivo Tarantino, Director of External Relations at Altrocono – but in the end, the tireless commitment with which we immediately defended consumer protection paid off.

In recent years, both companies have made numerous attempts to reverse the trend, with extreme technical possibilities that had nothing to do with the heart of the problem in question: patients who were denied access to a disease as serious as maculopathy and health care, who had to pay tens of millions of euros because of the odious illegal cartels of the two pharmaceutical companies. About NovartisNovartis offers innovative healthcare solutions that meet the changing needs of patients and companies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these requirements: innovative medicines, eye care and cost-saving generic drugs. Novartis is the only global company with leading positions in these areas. In 2015, the group had net sales of $49.4 billion, while research and development across the group was approximately $8.9 billion ($8.7 billion excluding impairment and depreciation expenses). Novartis Group companies employ approximately 118,000 full-time equivalents. Novartis products are available in 180 countries around the world. For more information, see The three companies Genentech, Roche and Novartis are linked by important structural and strategic links.